Jump to content
Crime Forum

Presently, 260 drug candidates are being evaluated in clinical / preclinical stages {RootsAnalysis}

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.


To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html


The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

§  Type of Therapy (Tx)

§  Prescription Drug

§  Prebiotics

§  Probiotics


§  Type of Molecule (Tx)

§  Small Molecules

§  Biologics


§  Target Indication (Tx+Dx)

§  Acne Vulgaris

§  Atopic Dermatitis

§  Clostridium difficile Infection

§  Colorectal Cancer

§  Crohn’s Disease

§  Diabetes

§  Irritable Bowel Syndrome

§  Lactose Intolerance

§  Lung Cancer

§  Nonalcoholic steatohepatitis (NASH)

§  Obesity

§  Ulcerative colitis


§  Therapeutic Area (Tx+Dx)

§  Autoimmune Disorders

§  Dental Disorders

§  Digestive and Gastrointestinal Disorders

§  Dermatological Disorders

§  Infectious Disease

§  Metabolic Disorders

§  Oncology

§  Others


§  Key Geographical Regions (Tx+Dx)

§  North America

§  Europe

§  Asia-Pacific and Rest of the World



The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:

§  4D Pharma

§  Armata Pharmaceuticals

§  Evelo Biosciences

§  Rebiotix (Acquired by Ferring Pharmaceuticals)

§  Seres Therapeutics

§  Vedanta Biosciences


Table of Contents

1.     Preface


2.     Executive Summary


3.     Introduction


4.     Microbiome Therapeutics: Market Landscape


5.     Company and Drug Profiles


6.     Microbiome Diagnostics: Market Landscape


7.     Fecal Microbiota Therapy (FMT)


8.     Attractiveness Competitiveness (AC) Matrix


9.     Microbiome Related Initiatives of Big Pharmaceutical Players


10.  Start-up Health Indexing


11.  Key Therapeutics Areas


12.  Funding and Investment Analysis


13.  Contract Services for Microbiome Therapeutics


14.  Big Data and Microbiome Therapeutics


15.  Microbiome Therapeutics: Market Forecast and Opportunity Analysis


16.  Microbiome Diagnostics: Market Forecast and Opportunity Analysis


17.  Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis


18.  Case Study: Microbiome-based Products in Other Industries


19.  Concluding Remarks


20.  Executive Insights


21.  Appendix I: Tabulated Data


22.  Appendix II: List of Companies and Organizations



To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415



Recommended Comments

There are no comments to display.

Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...